Keywords: Cetuximab, Epidermal Growth Factor Receptor, Lapatinib, Protein Tyrosine Kinase, Saracatinib, Trastuzumab, Animal Experiment, Animal Model, Antineoplastic Activity, Article, Breast Cancer, Breast Cancer Cell Line, Cancer Inhibition, Cancer Resistance, Cell Invasion, Cell Migration, Cell Proliferation, Cell Survival, Controlled Study, Drug Efficacy, Drug Sensitivity, Enzyme Activation, Enzyme Inhibition, Enzyme Linked Immunosorbent Assay, Female, Human, Human Cell, Immunoprecipitation, In Vitro Study, In Vivo Study, Mouse, Nonhuman, Signal Transduction, Treatment Duration, Tumor Invasion, Western Blotting, Wound Healing,
Affiliations: *** IBB - CNR ***
Departments of Medicina Clinica e Chirurgia, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy
Istituto di Biostrutture e Bioimmagini, CNR, Via Pietro Castellino 111, 80131 Naples, Italy
Neuroscienze e Scienze Riproduttive ed Odontostomatologiche, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy
Sanità Pubblica, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy
Medicina Molecolare e Biotecnologie Mediche, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy
Department of Microbiology, Immunology and Cancer Biology, Cancer Center, University of Virginia Health System, Charlottesville, Virginia 22908, United States
Sanit Pubblica, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy
Moasser, M.M., The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis (2007) Oncogene, 26, pp. 6469-6487. , 10.1038/sj.onc.1210477, 3021475, 17471238
Moasser, M.M., Targeting the function of the HER2 oncogene in human cancer therapeutics (2007) Oncogene, 26, pp. 6577-6592. , 10.1038/sj.onc.1210478, 3071580, 17486079
Burris, H.A., Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway (2013) Cancer Chemother Pharmacol, , Epub ahead of print
Verma, S., Miles, D., Gianni, L., Krop, I.E., Welslau, M., Baselga, J., Pegram, M., Blackwell, K., Trastuzumab emtansine for HER2-positive advanced breast cancer (2012) N Engl J Med, 367, pp. 1783-1791. , 10.1056/NEJMoa1209124, 23020162, EMILIA Study Group
Rusnak, D.W., Affleck, K., Cockerill, S.G., Stubberfield, C., Harris, R., Page, M., Smith, K.J., Lackey, K., The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer (2001) Cancer Res, 61, pp. 7196-7203
Rusnak, D.W., Lackey, K., Affleck, K., Wood, E.R., Alligood, K.J., Rhodes, N., Keith, B.R., Gilmer, T.M., The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo (2001) Mol Cancer Ther, 1, pp. 85-94
Geyer, C.E., Forster, J., Lindquist, D., Chan, S., Romieu, C.G., Pienkowski, T., Jagiello-Gruszfeld, A., Cameron, D., Lapatinib plus capecitabine for HER2-positive advanced breast cancer (2006) N Engl J Med, 355, pp. 2733-2743. , 10.1056/NEJMoa064320, 17192538
Scaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P.D., Sánchez, G., Baselga, J., Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor (2010) Clin Cancer Res, 16, pp. 2688-2695. , 10.1158/1078-0432.CCR-09-3407, 3243489, 20406840
Rexer, B.N., Arteaga, C.L., Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications (2012) Crit Rev Oncol, 17, pp. 1-16
Yeatman, T.J., A renaissance for SRC (2004) Nat Rev Cancer, 4, pp. 470-480. , 10.1038/nrc1366, 15170449
Playford, M.P., Vadali, K., Cai, X., Focal adhesion kinase regulates cell-cell contact formation in epithelial cells via modulation of Rho (2008) Exp Cell Res, 314, pp. 3187-3197. , 10.1016/j.yexcr.2008.08.010, 2613854, 18773890
Nagaraj, N.S., Washington, M.K., Merchant, N.B., Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth (2011) Clin Cancer Res, 17, pp. 483-493. , 10.1158/1078-0432.CCR-10-1670, 3079196, 21266529
Wheeler, D.L., Iida, M., Kruser, T.J., Nechrebecki, M.M., Dunn, E.F., Armstrong, E.A., Huang, S., Harari, P.M., Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab (2009) Cancer Biol Ther, 8, pp. 696-703. , 10.4161/cbt.8.8.7903, 2895567, 19276677
Yoshida, T., Zhang, G., Haura, E.B., Targeting epidermal growth factor receptor: central signaling kinase in lung cancer (2010) Biochem Pharmacol, 80, pp. 613-623. , 10.1016/j.bcp.2010.05.014, 20519133
Zhang, S., Huang, W.C., Li, P., Guo, H., Poh, S.B., Brady, S.W., Xiong, Y., Yu, D., Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways (2011) Nat Med, 17, pp. 461-469. , 10.1038/nm.2309, 3877934, 21399647
Rexer, B.N., Ham, A.J., Rinehart, C., Hill, S., Granja-Ingram, M., González-Angulo, A.M., Mills, G.B., Arteaga, C.L., Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition (2011) Oncogene, 30, pp. 4163-4174. , 10.1038/onc.2011.130, 3204390, 21499296
Sheffield, L.G., C-Src activation by ErbB2 leads to attachment-independent growth of human breast epithelial cells (1998) Biochem Biophys Res Commun, 250, pp. 27-31. , 10.1006/bbrc.1998.9214, 9735325
Belsches-Jablonski, A.P., Biscardi, J.S., Peavy, D.R., Tice, D.A., Romney, D.A., Parsons, S.J., Src family kinases and HER2 interactions in human breast cancer cell growth and survival (2001) Oncogene, 20, pp. 1465-1475. , 10.1038/sj.onc.1204205, 11313890
Tan, M., Li, P., Klos, K.S., ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis (2005) Cancer Res, 65, pp. 1858-1867. , 10.1158/0008-5472.CAN-04-2353, 15753384
Kurebayashi, J., Otsuki, T., Tang, C.K., Kurosumi, M., Yamamoto, S., Tanaka, K., Mochizuki, M., Sonoo, H., Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6 (1999) Br J Cancer, 79, pp. 707-717. , 10.1038/sj.bjc.6690114, 2362677, 10070858
Tanner, M., Kapanen, A.I., Junttila, T., Raheem, O., Grenman, S., Elo, J., Elenius, K., Isola, J., Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer (2004) Mol Cancer Ther, 3, pp. 1585-1592
Bianco, R., Rosa, R., Damiano, V., Daniele, G., Gelardi, T., Garofalo, S., Tarallo, V., Tortora, G., Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells (2008) Clin Cancer Res, 14, pp. 5069-5080. , 10.1158/1078-0432.CCR-07-4905, 18694994
Melisi, D., Ishiyama, S., Sclabas, G.M., Fleming, J.B., Xia, Q., Tortora, G., Abbruzzese, J.L., Chiao, P.J., LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis (2008) Mol Cancer Ther, 7, pp. 829-840. , 10.1158/1535-7163.MCT-07-0337, 3088432, 18413796
Rosa, R., Marciano, R., Malapelle, U., Formisano, L., Nappi, L., D'Amato, C., D'Amato, V., Bianco, R., Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models (2013) Clin Cancer Res, 19, pp. 138-147. , 10.1158/1078-0432.CCR-12-1050, 23166225
Liu, Z., Zhang, B., Liu, K., Ding, Z., Hu, X., Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition (2012) PLoS One, 7, pp. e40480. , 10.1371/journal.pone.0040480, 3405072, 22848381
Schneider, T., Osl, F., Friess, T., Stockinger, H., Scheuer, W.V., Quantification of human Alu sequences by real-time PCR-an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants (2002) Clin Exp Metastasis, 19, pp. 571-582. , 10.1023/A:1020992411420, 12498386
García-García, C., Ibrahim, Y.H., Serra, V., Calvo, M.T., Guzmán, M., Grueso, J., Aura, C., Scaltriti, M., Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy (2012) Clin Cancer Res, 18, pp. 2603-2612. , 10.1158/1078-0432.CCR-11-2750, 22407832
O'Brien, N.A., Browne, B.C., Chow, L., Wang, Y., Ginther, C., Arboleda, J., Duffy, M.J., Slamon, D.J., Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib (2010) Mol Cancer Ther, 9, pp. 1489-1502. , 10.1158/1535-7163.MCT-09-1171, 20501798
Chou, T.C., Talalay, P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors (1984) Adv Enzyme Regul, 22, pp. 27-55
Donepudi, M., Resh, M.D., C-Src trafficking and co-localization with the EGF receptor promotes EGF ligand-independent EGF receptor activation and signaling (2008) Cell Signal, 20, pp. 1359-1367. , 10.1016/j.cellsig.2008.03.007, 2459337, 18448311
Biscardi, J.S., Maa, M.C., Tice, D.A., Cox, M.E., Leu, T.H., Parsons, S.J., C-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function (1999) J Biol Chem, 274, pp. 8335-8343. , 10.1074/jbc.274.12.8335, 10075741
Tice, D.A., Biscardi, J.S., Nickles, A.L., Parsons, S.J., Mechanism of biological synergy between cellular Src and epidermal growth factor receptor (1999) Proc Natl Acad Sci U S A, 96, pp. 1415-1420. , 10.1073/pnas.96.4.1415, 15477, 9990038
Wu, W., Graves, L.M., Gill, G.N., Parsons, S.J., Samet, J.M., Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation (2002) J Biol Chem, 277, pp. 24252-24257. , 10.1074/jbc.M200437200, 11983694
Mueller, K.L., Powell, K., Madden, J.M., Eblen, S.T., Boerner, J.L., EGFR tyrosine 845 phosphorylation-dependent proliferation and transformation of breast cancer cells require activation of p38 MAPK (2012) Transl Oncol, 5, pp. 327-334. , 10.1593/tlo.12163, 3468924, 23066441
Rexer, B.N., Ghosh, R., Narasanna, A., Estrada, M.V., Chakrabarty, A., Song, Y., Engelman, J.A., Arteaga, C.L., Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2 (2013) Clin Cancer Res, 19, pp. 5390-5401. , 10.1158/1078-0432.CCR-13-1038, 23948973
Xia, W., Petricoin, E.F., Zhao, S., Liu, L., Osada, T., Cheng, Q., Wulfkuhle, J.D., Spector, N.L., An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models (2013) Breast Cancer Res, 15, pp. R85. , 10.1186/bcr3480, 3978995, 24044505
Duncan, J.S., Whittle, M.C., Nakamura, K., Abell, A.N., Midland, A.A., Zawistowski, J.S., Johnson, N.L., Johnson, G.L., Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer (2012) Cell, 149, pp. 307-321. , 10.1016/j.cell.2012.02.053, 3328787, 22500798
Mueller, K.L., Hunter, L.A., Ethier, S.P., Boerner, J.L., Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells (2008) Cancer Res, 68, pp. 3314-3322. , 10.1158/0008-5472.CAN-08-0132, 3878202, 18451158
De Luca, A., D'Alessio, A., Gallo, M., Maiello, M.R., Bode, A.M., Normanno, N., Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib (2014) Cell Cycle, 13, pp. 148-156. , 10.4161/cc.26899, 24200972
Rexer, B.N., Chanthaphaychith, S., Dahlman, K.B., Arteaga, C.L., Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells (2014) Breast Cancer Res, 16, pp. R9. , 10.1186/bcr3601, 3978602, 24451154
Zhang, D., Pal, A., Bornmann, W.G., Yamasaki, F., Esteva, F.J., Hortobagyi, G.N., Bartholomeusz, C., Ueno, N.T., Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells (2008) Mol Cancer Ther, 7, pp. 1846-1850. , 10.1158/1535-7163.MCT-08-0168, 2525738, 18644997
Moulder, S.L., Yakes, F.M., Muthuswamy, S.K., Bianco, R., Simpson, J.F., Arteaga, C.L., Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo (2001) Cancer Res, 61, pp. 8887-8895
Normanno, N., Campiglio, M., De, L.A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Menard, S., Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth (2002) Ann Oncol, 13, pp. 65-72
Mayer, E.L., Baurain, J.F., Sparano, J., Strauss, L., Campone, M., Fumoleau, P., Rugo, H., Llombart-Cussac, A., A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer (2011) Clin Cancer Res, 17, pp. 6897-6904. , 10.1158/1078-0432.CCR-11-0070, 21903773
Moasser, M. M., The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis (2007) Oncogene, 26, pp. 6469-6487. , 10. 1038/sj. onc. 1210477, 3021475, 17471238
Moasser, M. M., Targeting the function of the HER2 oncogene in human cancer therapeutics (2007) Oncogene, 26, pp. 6577-6592. , 10. 1038/sj. onc. 1210478, 3071580, 17486079
Burris, H. A., Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway (2013) Cancer Chemother Pharmacol, , Epub ahead of print
Rusnak, D. W., Affleck, K., Cockerill, S. G., Stubberfield, C., Harris, R., Page, M., Smith, K. J., Lackey, K., The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer (2001) Cancer Res, 61, pp. 7196-7203
Rusnak, D. W., Lackey, K., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Gilmer, T. M., The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo (2001) Mol Cancer Ther, 1, pp. 85-94
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Cameron, D., Lapatinib plus capecitabine for HER2-positive advanced breast cancer (2006) N Engl J Med, 355, pp. 2733-2743. , 10. 1056/NEJMoa064320, 17192538
Rexer, B. N., Arteaga, C. L., Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications (2012) Crit Rev Oncol, 17, pp. 1-16
Yeatman, T. J., A renaissance for SRC (2004) Nat Rev Cancer, 4, pp. 470-480. , 10. 1038/nrc1366, 15170449
Playford, M. P., Vadali, K., Cai, X., Focal adhesion kinase regulates cell-cell contact formation in epithelial cells via modulation of Rho (2008) Exp Cell Res, 314, pp. 3187-3197. , 10. 1016/j. yexcr. 2008. 08. 010, 2613854, 18773890
Nagaraj, N. S., Washington, M. K., Merchant, N. B., Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth (2011) Clin Cancer Res, 17, pp. 483-493. , 10. 1158/1078-0432. CCR-10-1670, 3079196, 21266529
Wheeler, D. L., Iida, M., Kruser, T. J., Nechrebecki, M. M., Dunn, E. F., Armstrong, E. A., Huang, S., Harari, P. M., Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab (2009) Cancer Biol Ther, 8, pp. 696-703. , 10. 4161/cbt. 8. 8. 7903, 2895567, 19276677
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., Wheeler, D. L., Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) Oncogene, 30, pp. 561-574. , 10. 1038/onc. 2010. 430, 3025039, 20956938
Rexer, B. N., Ham, A. J., Rinehart, C., Hill, S., Granja-Ingram, M., Gonz lez-Angulo, A. M., Mills, G. B., Arteaga, C. L., Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition (2011) Oncogene, 30, pp. 4163-4174. , 10. 1038/onc. 2011. 130, 3204390, 21499296
Sheffield, L. G., C-Src activation by ErbB2 leads to attachment-independent growth of human breast epithelial cells (1998) Biochem Biophys Res Commun, 250, pp. 27-31. , 10. 1006/bbrc. 1998. 9214, 9735325
Garc a-Garc a, C., Ibrahim, Y. H., Serra, V., Calvo, M. T., Guzm n, M., Grueso, J., Aura, C., Scaltriti, M., Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy (2012) Clin Cancer Res, 18, pp. 2603-2612. , 10. 1158/1078-0432. CCR-11-2750, 22407832
O'Brien, N. A., Browne, B. C., Chow, L., Wang, Y., Ginther, C., Arboleda, J., Duffy, M. J., Slamon, D. J., Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib (2010) Mol Cancer Ther, 9, pp. 1489-1502. , 10. 1158/1535-7163. MCT-09-1171, 20501798
Chou, T. C., Talalay, P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors (1984) Adv Enzyme Regul, 22, pp. 27-55
Biscardi, J. S., Maa, M. C., Tice, D. A., Cox, M. E., Leu, T. H., Parsons, S. J., C-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function (1999) J Biol Chem, 274, pp. 8335-8343. , 10. 1074/jbc. 274. 12. 8335, 10075741
Tice, D. A., Biscardi, J. S., Nickles, A. L., Parsons, S. J., Mechanism of biological synergy between cellular Src and epidermal growth factor receptor (1999) Proc Natl Acad Sci U S A, 96, pp. 1415-1420. , 10. 1073/pnas. 96. 4. 1415, 15477, 9990038
Wu, W., Graves, L. M., Gill, G. N., Parsons, S. J., Samet, J. M., Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation (2002) J Biol Chem, 277, pp. 24252-24257. , 10. 1074/jbc. M200437200, 11983694
Mueller, K. L., Powell, K., Madden, J. M., Eblen, S. T., Boerner, J. L., EGFR tyrosine 845 phosphorylation-dependent proliferation and transformation of breast cancer cells require activation of p38 MAPK (2012) Transl Oncol, 5, pp. 327-334. , 10. 1593/tlo. 12163, 3468924, 23066441
Rexer, B. N., Ghosh, R., Narasanna, A., Estrada, M. V., Chakrabarty, A., Song, Y., Engelman, J. A., Arteaga, C. L., Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2 (2013) Clin Cancer Res, 19, pp. 5390-5401. , 10. 1158/1078-0432. CCR-13-1038, 23948973
Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Johnson, G. L., Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer (2012) Cell, 149, pp. 307-321. , 10. 1016/j. cell. 2012. 02. 053, 3328787, 22500798
Mueller, K. L., Hunter, L. A., Ethier, S. P., Boerner, J. L., Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells (2008) Cancer Res, 68, pp. 3314-3322. , 10. 1158/0008-5472. CAN-08-0132, 3878202, 18451158
Rexer, B. N., Chanthaphaychith, S., Dahlman, K. B., Arteaga, C. L., Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells (2014) Breast Cancer Res, 16, pp. R9. , 10. 1186/bcr3601, 3978602, 24451154
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., Arteaga, C. L., Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2) -overexpressing breast cancer cells in vitro and in vivo (2001) Cancer Res, 61, pp. 8887-8895
Mayer, E. L., Baurain, J. F., Sparano, J., Strauss, L., Campone, M., Fumoleau, P., Rugo, H., Llombart-Cussac, A., A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer (2011) Clin Cancer Res, 17, pp. 6897-6904. , 10. 1158/1078-0432. CCR-11-0070, 21903773
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(283 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote